1Schindler AE. Progestins and the endometrium. Zentralbl Gynakol,1997,119[Suppl 2]:59-63.
2Niwa K, Morishita S, Murase T, et al. Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis. Jpn J Cancer Res, 1995,86(8):724-729.
3Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst,1997,89(15):1110-1116.
4Beresford SA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet, 1997,349:458-461.
5Amezcua CA, Lu JJ, Felix JC, et al. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol,2000,79(2): 169-176.
6Wang S, Pudney J, Song J, et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer. Gynecol Oncol,2003,88(2): 108-117.
7Abulafia O, Triest WE, Adcock JT, et al. The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia. Gynecol Onco1,1999,72(2):193-198.
8Jobo T, Kawaguehi M, Imai M, et al. Treatment for complex atypical hyperplasia of the endometriurth Eur J Gynaecol Oncol,2001,22(5):365-368.
9Perez-Medina T, Bajo J, Folgueira G, et al. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gyneeol Oncol,1999,73(2):299-304.
10Makarov OV, Sergeev PV, Sviridov NK et al. Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia. Vopr Onkol,2000,46(5):570-573.
